RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today.
Because of its ability to silence any gene once the sequence is known,
RNAi has been adopted as the research tool to discriminate gene function.
The companies will work together to develop and commercialize this
RNAi therapeutic target, with the possibility of additional assets, and will form a Joint Steering Committee to guide the asset's development program.
melanogaster that the proteins Dic1, Loq and Ago1 are involved in the miRNA pathway whereas Dic2, R2d2 and Ago2 are involved in the
RNAi pathway (Mukherjee and Hanley, 2010).
These lipid researchers continue to develop novel lipids specifically for the purpose of
RNAi delivery.
When we disrupt the expression of it with
RNAi, we observe multiple effects in immature stages as well as in adults," Vander Meer says.
Researchers used
RNAi to screen human cells to identify genes that help parkin tag damaged mitochondria.
Tekmira continues to build upon its leadership position and invest in its
RNAi technologies by making advancements in LNP potency, tolerability, biodistribution, targeting, process development, and manufacturing, as well as the evaluation of new
RNAi payloads.
Silence Therapeutics is a leading
RNAi therapeutics product and technology platform company with proprietary delivery systems.
The journal Nature Biotechnology reported earlier this year that efforts to develop new drugs based on
RNAi have gone
Benitec Limited (ASX:BLT) (PINK:BNIKF) holds a dominant position in expressed RNA interference (
RNAi)-based human therapeutics, with a transformational platform technology supported by a robust and extensive intellectual property portfolio.
Therapeutic applications of
RNAi; methods and protocols.
